Table 1.
Gene based burden test analysis of the multiplex cohort.
| Gene | Chr | No. of Variants a | Burden b | p |
|---|---|---|---|---|
| MYO5C | 15 | 4 | −1.6295 | 0.103214 |
| NOTCH1 | 9 | 4 | −1.3859 | 0.165765 |
| PPRC1 | 10 | 5 | −1.3563 | 0.174993 |
| ABCA1 | 9 | 2 | 1.2021 | 0.229316 |
| DNAH8 | 6 | 7 | −1.0906 | 0.275457 |
| LOXHD1 | 18 | 10 | −0.781 | 0.434797 |
| HSF1 | 8 | 3 | −0.6585 | 0.510208 |
| ADAMTS5 | 21 | 6 | 0.4399 | 0.659993 |
| MYO1C | 17 | 5 | 0.3498 | 0.726526 |
| ASXL3 | 18 | 4 | −0.1488 | 0.88168 |
| KIF1A | 2 | 2 | 0.1461 | 0.883868 |
| TLN2 | 15 | 2 | 0.1461 | 0.883868 |
| ATN1 | 12 | 3 | −0.1299 | 0.896626 |
| KIF26B | 1 | 4 | 0.0279 | 0.977741 |
a Total number of low-frequency functional variants observed in the multiplex sample set. b A positive stat means that the number of rare functional variants is increased in MS patients compared to healthy individuals.